Pathophysiology of type 2 diabetes mellitus: Potential role of incretin-based therapies

R. Keith Campbell, Michael E. Cobble, Timothy S. Reid, Mansur E. Shomali

Research output: Contribution to journalReview articlepeer-review

Abstract

The multifactorial nature of the pathogenesis of T2DM provides an opportunity to combine treatments that act upon different mechanisms. In addition to improving insulin resistance and pancreatic β-cell dysfunction, the GLP-1 agonists and DPP-4 inhibitors improve the impaired incretin response, as well as increase insulin secretion and reduce glucagon secretion, both in a glucose-dependent manner. As a result of these multiple actions, the GLP-1 agonists and DPP-4 inhibitors lower both fasting and postprandial glucose levels. The effects of GLP-1 agonists tend to be greater, probably because they produce pharmacologic levels of GLP-1 compared to physiologic levels with the DPP-4 inhibitors. Another difference is that unlike the DPP-4 inhibitors, the GLP-1 agonists also slow gastric emptying and promote satiety.

Original languageEnglish (US)
Pages (from-to)S5-S9
JournalJournal of Family Practice
Volume59
Issue number9 SUPPL. 1
StatePublished - Sep 1 2010

ASJC Scopus subject areas

  • Family Practice

Fingerprint

Dive into the research topics of 'Pathophysiology of type 2 diabetes mellitus: Potential role of incretin-based therapies'. Together they form a unique fingerprint.

Cite this